Insider Selling: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Sells 2,601 Shares of Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 2,601 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $11.72, for a total transaction of $30,483.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of NASDAQ MNTA opened at $11.78 on Friday. Momenta Pharmaceuticals, Inc. has a 1-year low of $9.51 and a 1-year high of $29.30. The business has a fifty day moving average of $11.32.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Friday, August 2nd. The biotechnology company reported ($1.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.74). The company had revenue of $5.18 million during the quarter, compared to analyst estimates of $9.20 million. Momenta Pharmaceuticals had a negative return on equity of 55.24% and a negative net margin of 324.41%. Momenta Pharmaceuticals’s revenue for the quarter was down 60.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.91) earnings per share. Analysts predict that Momenta Pharmaceuticals, Inc. will post -2.5 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Primecap Management Co. CA lifted its position in Momenta Pharmaceuticals by 0.8% during the 1st quarter. Primecap Management Co. CA now owns 3,080,660 shares of the biotechnology company’s stock worth $44,762,000 after buying an additional 23,965 shares in the last quarter. Norges Bank bought a new stake in Momenta Pharmaceuticals during the 4th quarter worth about $19,673,000. Westfield Capital Management Co. LP lifted its position in Momenta Pharmaceuticals by 89.4% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,206,964 shares of the biotechnology company’s stock worth $17,537,000 after buying an additional 569,604 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Momenta Pharmaceuticals by 10.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,118,942 shares of the biotechnology company’s stock worth $12,353,000 after buying an additional 103,474 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Momenta Pharmaceuticals by 26.7% during the 4th quarter. Geode Capital Management LLC now owns 1,059,114 shares of the biotechnology company’s stock worth $11,692,000 after buying an additional 223,085 shares in the last quarter. 98.22% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts have recently issued reports on the stock. ValuEngine raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday. BidaskClub raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. Cantor Fitzgerald set a $16.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, May 2nd. Finally, Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $22.23.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

See Also: Why do corrections happen?

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.